New wearable catches cancer cells directly from your bloodstream

0 0

By Matthew Griffin Enhanced Humans and Biotech 24th November 2021

WHY THIS MATTERS IN BRIEF

This is the cancer equivalent of 24/7 monitoring of patients cancers and treatments, and it’s a historic milestone.

Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trends, connect, watch a keynote, or browse my blog.

While we’ve seen many cancer treatment breakthroughs in the past few years, from cancer vaccines through to more sci-fi treatments that include nanobots drilling and choking cancer cells within the body, getting biopsies is still a major a burden for cancer patients and doctors alike. Now, a new prototype wearable device may just get rid of biopsies altogether. The novel wearable, tested in animals, can capture live cancer cells directly from a patient’s blood.

Molecular farming means your next vaccine could be grown in a plant

“Nobody wants to have a biopsy. If we could get enough cancer cells from the blood, we could use them to learn about the tumor biology and direct care for the patients. That’s the excitement of why we’re doing this,” said Daniel Hayes at the University of Michigan and senior author on the paper in Nature Communications.

Tumors are capable of releasing more than 1,000 cancer cells into the bloodstream in a minute, but current methods of capturing these cells are generally unsuccessful. All too often, blood draws come back with no cancer cells, and a typical sample contains no more than 10 of these cells.

Researchers new penny sized computer monitor bone health in real time

However, the new device could be used to continuously collect cancer cells leading to a much higher concentration of captured cells. In tests done on animals, the wearable collected 3.5 times as many cancer cells per milliliter of blood as was produced by samples collected by blood draw alone.

“It’s the difference between having a security camera that takes a snapshot of a door every five minutes or takes a video. If an intruder enters between the snapshots, you wouldn’t know about it,” says Sunitha Nagrath, Ph.D., associate professor of chemical engineering at UM, who led the development of the device.

Researchers 3D printed brain tumors to accelerate discovery of new treatments

But the benefits of the wearable are not just in the number of cells it can capture. Targeting cancer cells in the blood is also key to planning treatment. Most cancer cells can’t survive in the blood, but those who do are called metastases. Metastases are the real deadly cells, unlike the original tumor. Being able to capture them from the blood would result in key data for treating the disease compared to what is produced by conventional biopsies.

In order to test the device, the researchers injected adult dogs with human cancer cells. The dogs were connected to the device, which screened between 1 to 2 percent of their blood continuously while blood was drawn every 20 minutes.

Researchers are sequencing and tracking Covid-19's global progress in real time

The team now hopes to increase the blood processing rate and Hayes believes the device could begin human trials in three to five years. If successful, the novel wearable could be used to help improve human cancer treatments.

“This is the epitome of precision medicine, which is so exciting in the field of oncology right now,” said Hayes.

Matthew Griffin / About Author

Described by NASA as a "Walking Encyclopaedia of the Future" and one of the world’s most in demand keynote speakers Matthew Griffin, Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm, is a multi-award winning Futurist and strategic foresight expert, author, lecturer, mentor, podcast and YouTube host.

With a distinguished career running global business units at Atos, EMC, and IBM today Matthew helps leaders and titans of industry from all over the world explore the impact of the inter sections of technology, culture, and leadership, then helps them create high performance organisations that can continuously disrupt, outpace, and outthink their competition.

15 times author of the hit series the Codex of the Future series Matthew's ability to identify, track, and explain the impacts of hundreds of emerging technologies and trends on global business, culture, and society has earned him a powerful reputation and a roster of clients that include royal households, world leaders across the G7, G20, and G77, and many of the world's most recognised and exceptional organisations including ABB, Accenture, ABN Amro, Adidas, AON, ARM, BCG, Centrica, Citi Group, Coca Cola, Deloitte, Dentons, Disney, Dow, EY, Google, KPMG, Lego, Microsoft, Legal & General, LinkedIn, Nokia, Paramount, PepsiCo, PWC, Qualcomm, RWE, Samsung, T-Mobile, UBS, Visa, WIRED, WPP and hundreds of others.

Matthew is regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, and his mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.